Loading the session
Loading the session
Loading instrument
$3.27
−9.63%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +2.8% (SPY −1.6%, XLV +13.5%). 3 months: −39.0% (SPY −0.4%, XLV +15.5%). 1 year: −54.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: WVE, SPY and XLV · as of 4 Nov 2026
Closed at $3.62 on 4 Nov 2026: 83.3% below the 52-week high of $21.73 (9 Dec 2025) and 19.1% above the low of $3.04 (14 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
21.2M shares were sold short at the 15 Oct 2026 settlement; covering them would take 6.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $3.62 was 8.7% below its 50-day average ($3.97) and 50.2% below its 200-day average ($7.27). It has closed below the 200-day for 155 sessions, since 26 Mar 2026. The 50-day average crossed below the 200-day on 30 Apr 2026, 130 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
December 8, 2025
+147.26%October 16, 2024
+74.07%September 24, 2024
+53.37%